LabGenius Raises Over £40 Million to Expand Data-Driven Antibody Discovery Platform

LabGenius, a company based in London, has successfully raised more than £40.1 million in order to further expand its data-driven antibody discovery platform.

The drug discovery business LabGenius, which is based in London and is a pioneer in the application of machine learning for the development of novel therapeutic antibodies, made the announcement today that it has successfully completed a Series B fundraising round with a total amount of more than £40.1 million. To date, LabGenius has received more than 67.8 million euros in finance, which is increased by this investment.

The round was led by new investor M Ventures, which is the strategic and corporate venture capital arm of the science and technology company Merck. Other new investors, such as Octopus Ventures and LG Corp, also participated in the round. Existing investors, such as Atomico, Kindred Capital, Lux Capital, and Obvious Ventures, also participated in the round.

The Chief Executive Officer of LabGenius, Dr. James Field, made the following statement: "The ability to engineer complex multispecific antibodies has enormous potential value." Over the course of several years, the LabGenius team has been a pioneer in the development of EVATM, a discovery platform that is capable of systematically uncovering novel high-performing multispecific antibodies with designs that are not obvious. I am motivated by the unrelenting determination that our team has demonstrated in order to bring us to this significant milestone, and I am looking forward to collaborating with our investors as we speed up the development of both our platform and pipeline.